When voters went to the polls in 2020, the answer was clear – the American people want access to new kinds of medicine.

They’ve watched the opioid epidemic ruin the lives of loved ones and destroy entire communities, with nearly 50,000 people in the United States dying from opioid-involved overdoses in 2019.

So the people took action, voting for the right to choose how they want to treat their health conditions.

In South Dakota, where possession of cannabis edibles, hash, and concentrates could cost you up to 10 years in jail, voters legalized both medical and recreational cannabis use at the same time.

Mississippi voters also said “Yes” to legalizing medical cannabis.

In Oregon and Washington D.C., voters approved a measure to allow for the therapeutic use of psychedelic mushrooms. Psychedelics are already being used in Canada to help those who are terminally ill cope with anxiety and pain.

The stereotype of cannabis and psychedelics being for “lazy drug addicts” is eroding away.

The scientific community is acknowledging the health benefits of cannabis and psychedelics and their role in combating the opioid epidemic.

Research has found that cannabis can help relieve pain created from mild arthritis to cancer, while psychedelics are being studied for their potential ability to help with depression and their ability to treat other addictions to substances like nicotine and cocaine.

But as we mentioned earlier, the problem is that most people don’t understand the market potential of this new class of emerging medicine.

That’s OK, because at the National Institute for Cannabis Investors, we understand how this new class of medicine is disrupting the traditional medical market better than anyone… and we know exactly where investors should focus their attention.

Both cannabis and psychedelics are young industries. By 2028, the legal psychedelic drug market could be worth $10.7 billion, a 181.57% increase from sales of $3.8 billion in 2020.

For cannabis, legal sales totaled $17.5 billion in 2020 and could pass the $50 billion mark by 2025. An increase of 185.71% in just four years.

But remember this: You should never invest what you can’t afford to lose… and to access our official recommendations of stocks to buy, stop loses to enter, and when to sell… you will need to be a paid-up member.

But we still want to share our moneymaking watchlist of six companies that have the opportunity to be leaders in the cannabis and psychedelics industries and give you the opportunity to make a lot of money.

Moneymaking Watchlist Pick #1: Trulieve Cannabis Corp. (OTC: TCNNF)

Trulieve has had the most impressive run of any cannabis company in the United States.

From just one medical dispensary in 2015, Trulieve now accounts for 50% of all the medical cannabis sold in Florida. It has the most dispensaries in the state with 82 storefronts, and once it closes an acquisition with Harvest Health and Recreation (OTC: HRVSF), it will have 90 dispensaries in Florida alone.

Florida is one of the best states to have a foothold in right now because by 2025, research firm New Frontier Data projects that Florida will account for 7% of all marijuana sales in the U.S.

The only state that’s projected to sell more cannabis is California.

And Trulieve is expanding its business plan across the country to Pennsylvania and West Virginia.

Currently trading at $38 per share, Executive Director Don Yocham projects Trulieve could trade for $136 in the next 12 to 18 months.

Moneymaking Watchlist Pick #2: Ayr Wellness Inc. (OTC: AYRWF)

Ayr Wellness has cannabis operations in seven states and is also building a large footprint in Florida.

Remember that we just mentioned how Florida could account for 7% of all legal U.S. cannabis sales by 2025, and Ayr wants to make sure that it is in a good position to take advantage of those sales.

It currently has 35 dispensaries in the state, and it plans to have 42 open by the end of the year.

Ayr is also building its footprint in the medical market of Pennsylvania, which is projected to sell $1 billion worth of cannabis this year.

It has two stores open in Pennsylvania now and plans to have six open by the end of 2021.

Currently trading at $29.30 per share, Don Yocham projects that the Ayr stock price could climb to $111 per share in the next 12 to 18 months.

Moneymaking Watchlist Pick #3: Curaleaf Holdings Inc. (OTC: CURLF)

Curaleaf Holdings currently has the most dispensaries in the United States at 106 storefronts and the largest footprint in the country by operating in 23 states.

By the end of 2021, Curaleaf could also be the largest American cannabis company by revenue as it projects to generate $1.2 billion in sales.

Curaleaf also bought the largest vertically integrated medical cannabis company in Europe and serves more than 350,000 medical marijuana patients across the United States.

This is one of our favorite companies at the National Institute for Cannabis Investors, and Don Yocham believes that this stock is going to keep climbing and continue making investors more money.

Currently trading at $14.85 per share, Don projects it will trade for $35 in the next 12 to 18 months.

Moneymaking Watchlist Pick #4: COMPASS Pathways PLC (Nasdaq: CMPS)

Currently, as many as two-thirds of people with depression do not feel their condition improve with the first antidepressant that they

try. Up to one-third of these individuals will not respond positively to several different treatment attempts.

COMPASS Pathways has developed a drug candidate called COMP360, which is synthetic psilocybin, also known as the psychoactive compound found in “magic mushrooms.” COMP360 is in Stage 2 studies for the use of treatment-resistant depression (TRD) and is aimed to help those not improving from other antidepressant options.

The company expects the Stage 2 study to conclude by the end of 2021 and could even receive market exclusivity for COMP360 if it passes Stage 3 trials. That’s because it would become the only psilocybin pharmaceutical approved by regulators to treat depression.

If approved, COMP360 has a patient market of over 320 million people.

Moneymaking Watchlist Pick #5: Cybin Inc. (OTC: CLXPF)

Cybin is a psychedelic pharmaceutical company based out of Toronto, Canada.

It currently has four psychedelic drugs in its pipeline with its lead candidate, psilocybin drug CYB001, in Phase 2 trials as a potential treatment option for major depressive disorder.

Major depressive disorder is also known as clinical depression, which can cause problems with sleeping, eating, and day-to-day well-being.

It affects more than 16.1 million Americans in the United States in any given year.

Cybin also has two drugs in preclinical trials and is researching the use of another drug as a potential treatment option for neurological disorders.

Plus, the company announced on June 8 that it was sponsoring a new clinical trial with the University of Washington to address frontline doctors, nurses, and health-care workers who are dealing with depression, burnout, and anxiety.


We hope this Moneymaking Watchlist helps put you on the fast track to identifying the biggest profit opportunities in these exciting new markets.

To your investing success,

The National Institute for Cannabis Investors Staff Reports